PureTech launch­es an I/O start­up in­spired by NYU’s George Miller; SV adopts a new name

→ PureTech is launch­ing a new biotech, this time fo­cus­ing on the im­muno-on­col­o­gy work done by NYU’s George Miller. It’s named Ny­bo Ther­a­peu­tics, and like a lot of PureTech up­starts, the an­nounce­ment is long on rep­u­ta­tions/names and short on terms, for now. “Most sol­id, ma­lig­nant tu­mors es­tab­lish an im­muno­sup­pres­sive en­vi­ron­ment to ward off the body’s nat­ur­al de­fens­es. Dr. Miller’s work in pan­cre­at­ic duc­tal car­ci­no­ma has re­vealed that in­flam­ma­to­ry process­es dri­ve the im­muno­sup­pres­sion through cer­tain gam­ma delta T cells and macrophages,” said Joseph Bolen, Chief Sci­en­tif­ic Of­fi­cer of PureTech Health. “Our nov­el ap­proach builds on this find­ing and se­lec­tive­ly dis­rupts the im­muno­sup­pres­sion to po­ten­tial­ly have a ther­a­peu­tic ef­fect on can­cer.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.